CN111886237B - 二氢色烯衍生物 - Google Patents

二氢色烯衍生物 Download PDF

Info

Publication number
CN111886237B
CN111886237B CN201980020335.0A CN201980020335A CN111886237B CN 111886237 B CN111886237 B CN 111886237B CN 201980020335 A CN201980020335 A CN 201980020335A CN 111886237 B CN111886237 B CN 111886237B
Authority
CN
China
Prior art keywords
methyl
pyrano
spiro
dihydro
benzopyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980020335.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111886237A (zh
Inventor
坂仁志
上冈正儿
泽山裕介
桥诘美纪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd, Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Publication of CN111886237A publication Critical patent/CN111886237A/zh
Application granted granted Critical
Publication of CN111886237B publication Critical patent/CN111886237B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CN201980020335.0A 2018-03-20 2019-03-19 二氢色烯衍生物 Active CN111886237B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-052971 2018-03-20
JP2018052971 2018-03-20
PCT/JP2019/011439 WO2019181939A1 (ja) 2018-03-20 2019-03-19 ジヒドロクロメン誘導体

Publications (2)

Publication Number Publication Date
CN111886237A CN111886237A (zh) 2020-11-03
CN111886237B true CN111886237B (zh) 2025-02-07

Family

ID=67986459

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980020335.0A Active CN111886237B (zh) 2018-03-20 2019-03-19 二氢色烯衍生物

Country Status (21)

Country Link
US (3) US10807993B2 (https=)
EP (1) EP3770162B1 (https=)
JP (4) JP6733072B2 (https=)
KR (1) KR102799186B1 (https=)
CN (1) CN111886237B (https=)
AU (1) AU2019239481B2 (https=)
CA (1) CA3092255A1 (https=)
CY (1) CY1126034T1 (https=)
DK (1) DK3770162T3 (https=)
EA (1) EA202092206A1 (https=)
ES (1) ES2941771T3 (https=)
FI (1) FI3770162T3 (https=)
HU (1) HUE062256T2 (https=)
MX (1) MX2020009763A (https=)
MY (1) MY202583A (https=)
PH (1) PH12020551497A1 (https=)
PL (1) PL3770162T3 (https=)
PT (1) PT3770162T (https=)
SG (1) SG11202007979UA (https=)
TW (1) TWI899051B (https=)
WO (1) WO2019181939A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3770162T3 (pl) * 2018-03-20 2023-06-05 Sumitomo Pharma Co., Ltd. Pochodne dihydrochromenu
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2025100519A1 (ja) * 2023-11-09 2025-05-15 住友ファーマ株式会社 ジヒドロクロメン誘導体を含むがんの治療剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038459A2 (en) * 2005-09-27 2007-04-05 Novartis Ag Carboxyamine compounds and their use in the treatment of hdac dependent diseases
CN101854937A (zh) * 2007-09-10 2010-10-06 波士顿生物医药公司 新的stat3途径抑制剂和癌症干细胞抑制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045707A1 (en) 1999-12-21 2001-06-28 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US20090111805A1 (en) 2005-02-24 2009-04-30 Pfizer Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
EP1847542A1 (en) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
RU2018101897A (ru) * 2015-06-22 2019-07-24 Сумитомо Дайниппон Фарма Ко., Лтд. Бициклическое гетероциклическое амидное производное
CA2990583A1 (en) 2015-06-22 2016-12-29 Sumitomo Dainippon Pharma Co., Ltd. 1,4-disubstituted imidazole derivative
JP6896701B2 (ja) * 2016-02-26 2021-06-30 大日本住友製薬株式会社 イミダゾリルアミド誘導体
TW201821105A (zh) * 2016-10-20 2018-06-16 美商弗瑪治療公司 使用ｈｄａｃ１１抑制劑之方法
PL3770162T3 (pl) 2018-03-20 2023-06-05 Sumitomo Pharma Co., Ltd. Pochodne dihydrochromenu
JP2020019752A (ja) 2018-08-03 2020-02-06 大日本住友製薬株式会社 クロマン誘導体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038459A2 (en) * 2005-09-27 2007-04-05 Novartis Ag Carboxyamine compounds and their use in the treatment of hdac dependent diseases
CN101854937A (zh) * 2007-09-10 2010-10-06 波士顿生物医药公司 新的stat3途径抑制剂和癌症干细胞抑制剂

Also Published As

Publication number Publication date
KR102799186B1 (ko) 2025-04-23
CN111886237A (zh) 2020-11-03
US20230219970A1 (en) 2023-07-13
JP6733072B2 (ja) 2020-07-29
US20200216461A1 (en) 2020-07-09
MX2020009763A (es) 2020-10-08
JP2024123117A (ja) 2024-09-10
FI3770162T3 (fi) 2023-06-02
AU2019239481A1 (en) 2020-09-10
KR20200135401A (ko) 2020-12-02
CA3092255A1 (en) 2019-09-26
US20210002290A1 (en) 2021-01-07
EP3770162B1 (en) 2023-03-15
BR112020017481A8 (pt) 2022-12-06
CY1126034T1 (el) 2023-11-15
JPWO2019181939A1 (ja) 2020-06-18
SG11202007979UA (en) 2020-09-29
US10807993B2 (en) 2020-10-20
DK3770162T3 (da) 2023-04-24
EP3770162A4 (en) 2021-12-01
US11639357B2 (en) 2023-05-02
EP3770162A1 (en) 2021-01-27
PL3770162T3 (pl) 2023-06-05
HUE062256T2 (hu) 2023-10-28
MY202583A (en) 2024-05-09
US12398149B2 (en) 2025-08-26
JP7508620B2 (ja) 2024-07-01
ES2941771T3 (es) 2023-05-25
EA202092206A1 (ru) 2020-12-15
JP2023075288A (ja) 2023-05-30
NZ767234A (en) 2025-06-27
JP2020180140A (ja) 2020-11-05
AU2019239481B2 (en) 2022-11-24
BR112020017481A2 (pt) 2020-12-22
PT3770162T (pt) 2023-03-23
JP7247144B2 (ja) 2023-03-28
TWI899051B (zh) 2025-10-01
PH12020551497A1 (en) 2021-09-01
WO2019181939A1 (ja) 2019-09-26
TW201941774A (zh) 2019-11-01

Similar Documents

Publication Publication Date Title
JP7508620B2 (ja) ジヒドロクロメン誘導体
JP7618567B2 (ja) 架橋型光学活性２級アミン誘導体
AU2014259477A1 (en) 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors for the treatment of cancer
JPWO2019189732A1 (ja) 光学活性な架橋型環状２級アミン誘導体
WO2021043208A1 (en) 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof
CA3199157A1 (en) Methods of treating diseases and disorders
JP7129728B2 (ja) Ｆｇｆｒ４阻害剤として使用される縮環誘導体
JP7287929B2 (ja) ジヒドロクロメン誘導体を含有する医薬
JP2020019752A (ja) クロマン誘導体
EP1925309A1 (en) Novel anticancer concomitant drug
WO2021172359A1 (ja) Ｃｄｋ９阻害剤プロドラッグ及びそれを内封するリポソーム
HK40043696A (en) Dihydrochromene derivatives
HK40043696B (en) Dihydrochromene derivatives
AU2020342189B2 (en) 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof
BR112020017481B1 (pt) Derivados de di-hidrocromeno, seu uso e composição farmacêutica
WO2024255837A1 (zh) 一种enpp1抑制剂的晶型
EA041753B1 (ru) Производные дигидрохромена

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Osaka City, Osaka of Japan

Applicant after: SUMITOMO PHARMACEUTICALS CO.,LTD.

Address before: Osaka City, Osaka of Japan

Applicant before: Dainippon Sumitomo Pharma Co.,Ltd.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: No. 6-8, Doshucho 2-chome, Chuo-ku, Osaka City, Osaka Prefecture, Japan

Applicant after: SUMITOMO PHARMACEUTICALS CO.,LTD.

Address before: Osaka City, Osaka of Japan

Applicant before: SUMITOMO PHARMACEUTICALS CO.,LTD.

GR01 Patent grant
GR01 Patent grant